Jason N. Mock


Jason Mock is an intellectual property attorney that helps organizations of all sizes in every facet of the patent life cycle. Whether a client is developing and obtaining new patent rights, managing a complex portfolio, performing due diligence for a transaction, or enforcing or defending its rights, Jason has the experience to guide his clients and serve as a trusted advisor.

Jason’s practice spans industries including pharmaceuticals, diagnostics, biotechnology, synthetic biology and biomanufacturing, food science, and agriculture. He has a depth of knowledge to help his clients keep pace in changing environments and realize value from their IP. Jason’s clients range from startups and universities to multinational corporations. He is a member of the firm’s Chemical, Biotechnology, and Pharmaceutical Practice Group and the PTAB Trials Practice Group.

Presentations and Publications

  • J. Mock, T. Yan, and K. Sharon, “IPR proactive defense measures – strategies and considerations for patent owners,” PTAB Trial Insights (May 2016)
  • J. Mock, “Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions,” PTAB Trial Insights (January 2016)
  • Author, “Post-Grant Proceedings at the USPTO and the Rising Tide of Federal Circuit Appeals,” The Federal Circuit Bar Journal (September 2015)
  • Co-author, “The Road Ahead for Kyle Bass’s IPRs,” Law360 (August 2015)
  • Co-author, “Will New PTAB Rules Impact IPRs Filed by Kyle Bass Hedge Fund?” The National Law Review (August 2015)
  • Co-author, “Survey of State Laws Against Bad-Faith Patent Assertion,” Bloomberg BNA Patent, Trademark & Copyright Journal (August 2014)
  • Co-author, “Role of the Phospholipase A2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells,” Mol. Pharmaceuticals (2014)
  • Co-author, “Evidence for Distinct Mechanisms of Uptake and Antitumor Activity of Secretory Phospholipase A2 Responsive Liposomes in Prostate Cancer,” Integr. Biol. (2012)
  • Co-author, “Haloenol Pyranones and Morpholinones as Antineoplastic Agents of Prostate Cancer,” Bioorg. and Med. Chem. Letters (2012)
  • Co-author, “Secretory Phospholipase A2 Responsive Liposomes,” J. Pharm. Sci. (2011)
  • Co-author, Enhanced Antitumor Activity of Low-Dose Continuous Administration Schedules of Topotecan in Prostate Cancer,” Cancer Bio. and Therapy (2011)
01 February 2024 Press Releases

Foley Announces 23 New Partners

Foley & Lardner LLP has elected 23 lawyers to the firm’s partnership, effective February 1, 2024.
29 March 2023 Health Care Law Today

The BioPharma Patent Cliff: 2023 and Beyond

A “patent cliff” refers to the end of IP protection for a drug that has enjoyed market exclusivity since its launch. Various types of regulatory exclusivity can occasionally lengthen the protection for drugs, but generally when a drug loses patent protection we begin seeing generic competitors on the market.
27 February 2023 Health Care Law Today

Health Care & Life Sciences Sector Top Trends for 2023

Foley is primed to strategically advise health care and life sciences companies through every step of their journey and all stages of their lifecycle.
19 August 2020 Blogs

PTAB’s Motion to Amend Pilot Program: Review of Initial Results

We analyze the initial results of the pilot program for motions to amend ("MTA") and conclude that, while it is still early in development and subsequent results could lead to new insights, for now at least patent owners may be better off using alternative approaches such as reissue or ex parte reexamination.
31 March 2020 Article

COVID-19: Patent Procurement and Licensing

Public health officials have said that we can expect the coronavirus pandemic to last for months—and the underlying virus will likely be with us for the long term. Meanwhile, the response to the COVID-19 pandemic has included a flurry of innovation.
15 October 2019 Blogs

While Tempting, PTAB Requests for Rehearing Face Long Odds

When the PTAB renders a decision, one of the parties is almost certain to be unhappy. Providing appropriate advice in the face of an undesired outcome requires an understanding of the odds of changing the outcome.